and adults with chronic moderate-to-severe plaque psoriasis. In clinical trials, the most common adverse effect of this treatment was injection site reaction (ISR). This can occur in up to 49% of ...

The FDA has approved biosimilars for: While many psoriasis medications come as injections, apremilast is a psoriasis treatment that comes as a pill. If you can’t take any of these medications or ...

active psoriatic arthritis with coexistent plaque psoriasis and hidradenitis suppurativa. The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available ...

"With the addition of a single-injection administration regimen, we are further expanding options and enhancing the treatment experience for individuals with moderate-to-severe plaque psoriasis ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching among patients with psoriasis ...

On October 14, 2024, the FDA approved a 320-mg single dose of bimekizumab-bkzx (Bimzelx; UCB) in a 2-mL prefilled syringe and autoinjector; both forms are now commercially available in the US.

The Tremfya (trem-FYE-ah) ad starts with a woman in a dark room with patches of her skin seemingly on fire. Another woman ...

The following is a summary of “Bimekizumab efficacy and safety through 3 years in patients with moderate to severe plaque ...

Deucravacitinib significantly improved skin-related quality of life of patients with moderate to severe plaque psoriasis, ...

In studies, eight out of 10 patients with moderate-to-severe plaque-type ... prescribed to treat psoriasis. Biologics are a class of drugs usually administered by injection. These drugs alter ...

Biosimilar SB17 demonstrated clinical biosimilarity to reference ustekinumab after switching and maintained long-term ...